Response to: 'Mandatory, cost-driven switching from originator etanercept to its biosimilar SB4: Possible fallout on non-medical switching' by Cantini and Benucci

Bente Glintborg*, Anne Gitte Loft, Emina Omerovic, Oliver Hendricks, Asta Linauskas, Jakob Espesen, Kamilla Danebod, Dorte Vendelbo Jensen, Henrik Nordin, Emil Barner Dalgaard, Stavros Chrysidis, Salome Kristensen, Johnny Lillelund Raun, Hanne Lindegaard, Natalia Manilo, Susanne Højmark Jakobsen, Inger Marie Jensen Hansen, Dorte Dalsgaard Pedersen, Inge Juul Sørensen, Lis Smedegaard AndersenJolanta Grydehøj, Frank Mehnert, Niels Steen Krogh, Merete Lund Hetland

*Corresponding author for this work

Research output: Contribution to journalComment/debateResearch

Original languageEnglish
Article numbere14
JournalAnnals of the Rheumatic Diseases
Volume79
Issue number2
Number of pages2
ISSN0003-4967
DOIs
Publication statusPublished - Feb 2020

Keywords

  • anti-tnf
  • DMARDs (biologic)
  • epidemiology
  • outcomes research

Cite this